Lausanne university hospital

What Lausanne university hospital does

Lausanne University Hospital (CHUV) is a public academic medical center and one of five Swiss university hospitals, designated as the reference hospital for general, specialized, and ultra-specialized care across French-speaking Switzerland. Operated as a service of the Canton of Vaud under the Department of Health and Social Affairs, CHUV runs 17 clinical and medico-technical departments and operates with a disclosed CHF 2 billion annual budget. It integrates clinical care, biomedical research, and teaching through formal collaborations with the University of Lausanne (UNIL) Faculty of Biology and Medicine and EPFL, and it has been ranked among the World's Best Hospitals by Newsweek every year since 2019.

CHUV's technology base spans AI-driven clinical decision support, neuroprosthetics, advanced radiotherapy, cellular therapy, and population-scale research platforms. The flagship AI asset is the HERACLES machine-learning algorithm, deployed inside the Sepsis Learning Health System and validated on 97,559 patient stays, with documented reductions in in-hospital and 90-day sepsis mortality. Proprietary clinical devices include WIMAGINE brain implants and an adaptive-AI digital bridge for thought-controlled walking in spinal cord injury (with EPFL, CEA and ONWARD Medical), a Parkinson's neuroprosthetic (with Inserm and University of Bordeaux), FLASH radiotherapy pioneered clinically since 2018, CAR-T cell immunotherapy for pediatric leukemia (with Seattle Children's Hospital), biological bandages for burns, and the LymphoDrain system spun out as Lymphatica. Longitudinal cohorts — CoLaus|PsyCoLaus (6,700+ participants, 15+ years, 470+ publications) and HypnoLaus — anchor a population-health data moat.

The revenue model is anchored in Swiss mandatory health insurance (LAMal) and Canton of Vaud public financing, supplemented by a fee-for-service international patient channel (medical directorate review, CHF 400 non-refundable pre-payment), competitive research grants (SNSF, EMA, IMI, Eurostars, Michael J. Fox Foundation), philanthropic flows via Fondation CHUV, and emerging technology-transfer and equity optionality through PACTT (Lymphatica, ONWARD Medical, Theryq). Patient acquisition is referral-driven for Swiss residents and case-by-case medical-file review for international patients, with the new CHF 204.5M Children's Hospital (opened May 14, 2025) representing the most significant recent capacity expansion.

Name

Lausanne university hospital

Legal name

Lausanne University Hospital (CHUV)

Website

https://lausanneuniversityhospital.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lausanne University Hospital (CHUV) is a Swiss public academic medical center and one of five Swiss university hospitals, delivering general and specialized clinical care, research, and teaching across 17 departments, funded primarily by Canton of Vaud with a CHF 2 billion annual budget.

Ownership category

akta.pro rank

Product category

Academic Hospital Services

NAICS

General Medical and Surgical Hospitals (622110), Hospitals (622), Health Care and Social Assistance (62)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Hospitals (8060)

akta.pro primary industry

Critical Access & Rural Hospitals (HLAFAAAG)

Keywords

• Academic hospital services
• Specialized medical care
• Clinical research programs
• Medical education training
• Healthcare innovation

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others

Revenue model

1. Swiss Health Insurance (LAMal): CHUV invoices Swiss health insurance companies directly according to the LAMal federal law or contracts with insurance companies for Swiss residents.
2. International Patient Services: Fee-for-service treatment for international patients following medical file review, with pre-payment and cost estimates provided in advance.
3. Government Funding: Annual budget of 2 billion Swiss francs, financed by the State of Vaud as a public academic healthcare institution (service of Canton of Vaud attached to Department of Health and Social Affairs).

Go-to-market motion2 records

Distribution channels7 records

Marketing channels10 records

Core offering

CHUV is a Swiss public academic medical center providing general, specialized, and ultra-specialized medical care across 17 clinical departments to residents of Canton of Vaud, French-speaking Switzerland, and international patients. The hospital integrates clinical care with biomedical research and teaching in collaboration with University of Lausanne and EPFL, operating as a service of the Canton of Vaud with an annual budget of approximately 2 billion Swiss francs. It pioneers advanced treatments including FLASH radiotherapy, brain-computer interfaces, AI-powered sepsis detection, CAR-T cell therapy, and biological bandages.

Product overview

Lausanne University Hospital (CHUV) is a Swiss academic medical center offering integrated healthcare services, research programs, and innovative medical treatments. The portfolio includes AI-powered clinical decision support systems (HERACLES sepsis algorithm, Sepsis Learning Health System), neuroprosthetic devices (Parkinson's neuroprosthetic, spinal cord stimulation system, digital bridge BCI), advanced radiotherapy (FLASH), biological wound care (biological bandages, LymphoDrain), and cellular therapies (CAR-T immunotherapy). The hospital operates the new Children's Hospital (opening May 2025) and conducts population health studies (CoLaus|PsyCoLaus, HypnoLaus) alongside digital health applications like POCOS for chronic pain management.

Differentiator

Problem solved

Functional benefit

Brands

• In Vivo Magazine: Multi award-winning magazine published by CHUV offering an overview of medical innovation in French-speaking Switzerland and throughout the world.
• Fondation CHUV
• NeuroRestore
• COVI-Preg

Products and services

• General Hospital Care
• Children's Hospital
• International Patient Services
• Day Patient Services
• Hôtel des Patients
• CAR-T Cell Immunotherapy
• FLASH Radiotherapy Treatment
• Digital Bridge Brain-Spine Interface
• Parkinson's Neuroprosthetic
• Sepsis Learning Health System (SLHS) with HERACLES Algorithm
• Biological Bandages
• LymphoDrain System Treatment
• Glioblastoma Clinical Trials
• Post-Mortem Angiography Forensic Service
• SARS-CoV-2 Blood Test
• COVI-Preg International Registry

Quantifiable outcome

• In-hospital mortality decreased from 20.54% to 15.27% and 90-day mortality from 32.99% to 26.11% for sepsis patients with AI-powered Sepsis Learning Health System
• +6 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability11 records

Feature12 records

Partnerships

21 partnerships are on record, tiered core, major and minor.

• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 March 2020CHUV coordinating Switzerland's participation in WHO Solidarity international study testing four experimental COVID-19 treatments (remdesivir, hydroxychloroquine, lopinavir/ritonavir combinations). 16 participating hospital centers in Switzerland.
• EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerCollaboration on brain-computer interface research including WIMAGINE® brain implants, digital bridge for spinal cord injury, and Parkinson's neuroprosthetic. EPFL/CHUV/UNIL neuroscience team led by Grégoire Courtine. Also collaborated on SARS-CoV-2 blood test development (S protein production by Didier Trono's team) and LymphoDrain project with EPFL engineers.
• CEA (Commissariat à l'énergie atomique et aux énergies alternatives)coreTechnology or IntegrationCEA developed WIMAGINE® devices for brain implants above motor cortex region. CEA head of BCI program Guillaume Charvet contributed adaptive AI algorithms for real-time movement decoding. Collaboration with CEA/CHUGA/UGA on brain-spine interface research.
• University of Lausanne (UNIL)coreStrategic or Co-development PartnerCollaboration on neuroscience research including Courtine and Bloch professorships. CHUV is affiliated with Faculty of Biology and Medicine at UNIL as one of five Swiss academic public health care centers.
• ONWARD MedicalcoreStrategic or Co-development PartnerCompany developing commercial version of digital bridge technology for spinal cord injury and Parkinson's neuroprosthetic. Received European Commission support through European Innovation Council (EIC) along with CEA and EPFL. Recently listed on Euronext.
• Inserm (Institut national de la santé et de la recherche médicale, France)majorStrategic or Co-development PartnerCollaboration on Parkinson's neuroprosthetic with Dr Erwan Bezard from Inserm, University of Bordeaux. Also collaborated on sleep and cardiovascular health research with Paris Cardiovascular Research Centre.
• University of BordeauxmajorStrategic or Co-development PartnerCollaboration through Dr Erwan Bezard on preclinical models of Parkinson's disease essential for neuroprosthetic development.
• Seattle Children's HospitalcoreStrategic or Co-development PartnerCollaboration on CAR-T cell immunotherapy for lymphoblastic leukemia in children and young adults. Initial clinical tests on 40 young people conducted at Seattle Children's Hospital 2014-2016. Clinical study scheduled at CHUV for 2020.
• Swiss Vaccine Research Institute (SVRI)coreTechnology or IntegrationCollaboration on SARS-CoV-2 blood test development. SVRI's technological facilities enabled rapid development of the test using Luminex technology and trimeric S protein structure.
• CERNmajorStrategic or Co-development PartnerCollaboration between Theryq and CERN to develop FLASH radiation therapy specifically targeting superficial tumors with electron beams of 6 or 9 megaelectron volts.
• GMP ArchitektenminorOthersArchitecture firm from Hamburg that developed design for new CHF 204.5 million Children's Hospital project along with Ferrari Architectes in Lausanne.
• Ferrari ArchitectesminorOthersLausanne-based architecture firm that collaborated with GMP Architekten on Children's Hospital design.
• Corona Immunitas ProgrammemajorStrategic or Co-development PartnerSwiss research programme for population studies using CHUV-developed SARS-CoV-2 blood test.
• Paris Cardiovascular Research CentremajorStrategic or Co-development PartnerCollaboration on sleep and cardiovascular health study with 10,157 adults in Paris (EPP3 cohort) combined with Swiss HypnoLaus/CoLaus study data.
• LymphaticacoreStrategic or Co-development PartnerStart-up company formed from LymphoDrain project for artificial lymphatic vessel system. First clinical study planned with about 20 patients in 2020.
• Federal Office of Public Health (FOPH)coreStrategic or Co-development PartnerCollaboration with FOPH on Swiss participation in WHO Solidarity COVID-19 study.
• Zurich University HospitalmajorStrategic or Co-development PartnerCollaboration on COH-FIT pandemic research with Roland von Känel heading German-speaking Switzerland participation.
• PACTT (UNIL-CHUV Technology Transfer Office)coreChannel Partner/ Reseller/ DistributorPreferred contact for collaboration, partnership or association with UNIL-CHUV researchers. Establishes contacts with industrial and financial investors for commercialization of research results.
• University of BernemajorStrategic or Co-development PartnerProf Alice Panchaud holds professorship of pharmacy at University of Berne while working at CHUV pharmacy.
• University of Geneva (UNIGE)coreStrategic or Co-development PartnerCollaboration on virtual reality immune response research led by Prof Andrea Serino (CHUV) and Prof Camilla Jandus (UNIGE). Published in Nature Neuroscience.
• Federal Office of Public Health (FOPH)coreStrategic or Co-development PartnerFOPH collaborated on Solidarity study and various COVID-19 research initiatives.

Scale indicators46 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• Karolinska University Hospital: Karolinska University Hospital is Sweden's premier academic medical center, affiliated with Karolinska Institutet. It mirrors CHUV's combination of publicly funded tertiary care, translational research and innovation-driven specialty programs in cell therapy and neuroprosthetics.
• King's College Hospital (NHS): King's College Hospital is a major London teaching hospital linked to King's College London, operating in the public NHS system. Comparable to CHUV in combining clinical service, research and teaching missions under public-funder constraints and similar prestige dynamics.
• Charité - Universitätsmedizin Berlin: Charité is Europe's largest university hospital and a direct analogue to CHUV as a publicly funded, research-intensive academic medical center. Comparable as a benchmark for translational research scale, specialty programs and pharma-sponsored trial capacity.
• University Hospital Basel: University Hospital Basel is the third of the five Swiss university hospitals, with equivalent specialist care and academic mission. It competes with CHUV for advanced clinical trials, top researchers and grant funding within the Swiss academic health ecosystem.
• University Hospital Zurich (USZ): USZ is the largest of Switzerland's five university hospitals and anchors German-speaking Switzerland's academic medicine. It offers the same university-affiliated inpatient, outpatient and research mix as CHUV and competes for international patient referrals across Switzerland.
• Inselspital - Bern University Hospital: Inselspital is the Bernese member of the five Swiss university hospitals, providing the same mix of tertiary referral care, university-linked teaching and translational research. It competes head-to-head with CHUV for pharmaceutical trials, residency talent and SNSF grants.
• University Hospital of Geneva (HUG): HUG is the sister Swiss French-speaking university hospital and CHUV's closest peer, delivering a comparable scope of general and specialty care plus university-linked research under the same LAMal funding regime. It is the only direct competitor for tertiary referrals across Suisse romande.

Broad incumbents

• Mayo Clinic: Mayo Clinic is a globally top-ranked academic medical center that, like CHUV, attracts complex international patients, performs pioneering research and has consistently placed in the Newsweek World's Best Hospitals top 10. Comparable as a brand and research benchmark rather than a direct Swiss competitor.
• Assistance Publique - Hôpitaux de Paris (AP-HP): AP-HP is Europe's largest hospital system with a teaching/research mandate akin to CHUV's, anchored by Université Paris Cité. It is a relevant comparator for publicly funded academic governance models and population-health cohort design, even though it operates at roughly 10x CHUV's scale.
• Mass General Brigham (Massachusetts General Hospital): Mass General Brigham is the largest Harvard-affiliated hospital system and a global benchmark for academic medicine with similar Newsweek top-10 positioning. Comparable to CHUV in combining specialty care, AI-driven clinical programs and biotech partnership models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/157828160908558
• LinkedInlinkedin.com/company/chuv
• Instagraminstagram.com/chuvlausanne
• Xx.com/chuvlausanne

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lausanne university hospital